Samsung Bioepis Gets Higher Strength Trastuzumab Nod
Both 150mg And 420mg Vials Of Ontruzant Biosimilar Now Approved
Although Merck has not yet debuted the Ontruzant version of trastuzumab developed by Samsung Bioepis in the US, the firm can now look to introduce two strengths of the Herceptin biosimilar, ahead of plans to spin off its biosimilar assets into a new company next year.
